TAIKO PHARMACEUTICAL CO., LTD. Logo

TAIKO PHARMACEUTICAL CO., LTD.

Manufactures OTC medicines and infection control products, specializing in GI remedies.

4574 | T

Overview

Corporate Details

ISIN(s):
JP3442200006
LEI:
Country:
Japan
Address:
吹田市内本町三丁目34番14号

Description

Taiko Pharmaceutical Co., Ltd. is a pharmaceutical company that manufactures and sells over-the-counter (OTC) medicines and infection control products. The company specializes in gastrointestinal remedies, with its flagship product, Seirogan, being a long-standing treatment for conditions such as diarrhea, loose stools, and symptoms of food and water poisoning. Its product portfolio also includes other general-use pharmaceuticals and quasi-drugs. Alongside its core pharmaceutical business, Taiko Pharmaceutical is engaged in the development and marketing of sanitation and infection management solutions. The company operates on the principles of Independence, Interdependence, and Creativity, serving both domestic and international markets.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-08-08 08:35
確認書
Japanese ZIP 8.0 KB
2025-08-08 08:34
半期報告書-第80期(2025/01/01-2025/12/31)
Japanese ZIP 197.8 KB
2025-04-01 08:45
臨時報告書
Japanese ZIP 22.1 KB
2025-03-28 07:36
臨時報告書
Japanese ZIP 19.1 KB
2025-03-28 07:35
内部統制報告書-第79期(2024/01/01-2024/12/31)
Japanese ZIP 22.1 KB
2025-03-28 07:33
確認書
Japanese ZIP 8.1 KB
2025-03-28 07:32
有価証券報告書-第79期(2024/01/01-2024/12/31)
Japanese ZIP 1011.8 KB
2024-08-09 08:34
確認書
Japanese ZIP 8.0 KB
2024-08-09 08:33
半期報告書-第79期(2024/01/01-2024/12/31)
Japanese ZIP 210.9 KB
2024-05-10 08:37
確認書
Japanese ZIP 8.0 KB
2024-05-10 08:35
四半期報告書-第79期第1四半期(2024/01/01-2024/03/31)
Japanese ZIP 164.9 KB
2024-04-01 08:14
臨時報告書
Japanese ZIP 23.7 KB
2024-03-28 07:30
内部統制報告書-第78期(2023/01/01-2023/12/31)
Japanese ZIP 22.1 KB
2024-03-28 07:28
確認書
Japanese ZIP 8.1 KB
2024-03-28 07:26
有価証券報告書-第78期(2023/01/01-2023/12/31)
Japanese ZIP 1.1 MB

Automate Your Workflow. Get a real-time feed of all TAIKO PHARMACEUTICAL CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TAIKO PHARMACEUTICAL CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TAIKO PHARMACEUTICAL CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.